XOMA Royalty (XOMA) has amended its collaboration, originally established in 2006, with Takeda (TAK) through a strategic royalty share transaction. Takeda’s royalty and milestone payment obligations to XOMA Royalty related to mezagitamab will be reduced, and XOMA Royalty will receive payments based on low to mid-single-digit royalties and milestones across a basket of nine development-stage assets that are held within Takeda’s externalized assets portfolio. Prior to amending the collaboration, XOMA Royalty held a mid-single digit royalty and $16.25M in potential milestones associated with mezagitamab. Going forward, XOMA Royalty will retain a low single-digit royalty entitlement on mezagitamab and up to $13M in milestones.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XOMA:
- Strategic Acquisitions and Partnerships Drive Xoma’s Growth: A Buy Recommendation
- Generation Bio price target lowered to $5.50 from $7 at Wedbush
- Generation Bio downgraded to Hold from Buy at Jefferies
- Xoma to acquire Generation Bio for $4.2913 per share
- Buy Rating Maintained for XOMA Despite Rezolute Bio’s Trial Setback, Future Developments Anticipated